Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck

Parameswaran, Janaki; Burtness, Barbara

doi:10.1016/j.ijrobp.2017.03.003

Cited by 4 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are 3 main clinical and public health implications from this study, First, immunotherapy use in HNC care is relatively recent, and the mainstay immunotherapeutics, nivolumab and pembrolizumab, were approved by the US Food and Drug Administration for HNC only within the last decade. While several highquality randomized trials [7][8][9][10][11] have established safety and efficacy of these treatment options in HNC, there has been a paucity of clinical data describing the epidemiology of immunotherapy in HNC. Equitable access to care is a hallmark of high-quality cancer care, 28,29 and more data are needed to describe differential access to immunotherapy in a highly disparate cancer such as HNC.…”

Section: Clinical and Public Health Implicationsmentioning

confidence: 99%

“…In 2016, following landmark clinical trials, the US Food and Drug Administration approved immune checkpoint inhibitors (ICIs; interchangeably referred to as immunotherapy going forward) as an option for head and neck squamous cell carcinoma (HNSCC). These landmark trials, in addition to safety and efficacy, demonstrated improved survival for patients diagnosed with programmed cell death ligand 1–positive recurrent or metastatic HNSCC compared with treatment with platinum-based chemotherapy alone . Cytotoxic T-lymphocyte–associated antigen-4 and programmed cell death-1 are 2 immunomodulatory receptors expressed on T cells that are targeted by the available immunotherapy medications such as ipilimumab, nivolumab, and pembrolizumab .…”

Section: Introductionmentioning

confidence: 99%

“…These landmark trials, in addition to safety and efficacy, demonstrated improved survival for patients diagnosed with programmed cell death ligand 1-positive recurrent or metastatic HNSCC compared with treatment with platinum-based chemotherapy alone. 10,11 Cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death-1 are 2 immunomodulatory receptors expressed on T cells that are targeted by the available immunotherapy medications such as ipilimumab, nivolumab, and pembrolizumab. 12 However, while there are several previous and ongoing clinical trials establishing the treatment efficacy of immunotherapy, 5 there is very little clinical evidence of access to and receipt of immunotherapy among patients with HNC.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer

Ramkumar,

Bhardwaj,

Patel

et al. 2023

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

ImportanceThe US Food and Drug Administration approved immune checkpoint inhibitors (immunotherapy) for select cases of head and neck squamous cell carcinoma (HNSCC) in 2016. However, it is unclear whether there are clinical or sociodemographic differences among patients receiving immunotherapy as part of their care. Given the known disparities in head and neck cancer care, we hypothesized that there are differences in receipt of immunotherapy among patients with HNSCC based on clinical and nonclinical characteristics.ObjectiveTo characterize clinical and nonclinical factors associated with receipt of immunotherapy among older patients with HNSCC.Design, Setting, and ParticipantsThis retrospective cohort study included patients 65 years or older diagnosed with HNSCC (n = 4860) in a community oncology care setting. Electronic health records from Navigating Cancer were assessed from January 1, 2017, to April 30, 2022.Main Outcomes and MeasuresMultivariable logistic regression was used to characterize clinical (tumor stage [localized vs advanced] and anatomical subsite [oropharyngeal vs nonoropharyngeal]) and nonclinical (age, smoking history, race and ethnicity, sex, and marital status) factors associated with receipt of immunotherapy.ResultsIn the study cohort of 4860 patients, 3593 (73.9%) were men; 4230 (87.0%) were White and 630 (13.0%) were of other races. A total of 552 patients (11.4%) had received immunotherapy. After adjusting for covariates, in the final model, White patients with HNSCC had 80% increased odds of receiving immunotherapy (adjusted odds ratio [AOR], 1.80 [95% CI, 1.30-2.48]) compared with patients of other races. There were no statistically significant differences in the odds of receiving immunotherapy based on age, sex, or smoking history. Patients with nonoropharyngeal disease were significantly more likely to receive immunotherapy than those with oropharyngeal cancer (AOR, 1.29 [95% CI, 1.05-1.59]), as were those with advanced compared with local disease (AOR, 2.39 [95% CI, 1.71-3.34]).Conclusions and RelevanceThe findings of this cohort study suggest that among older patients with HNSCC, White patients may be more likely to receive immunotherapy as part of their care. Equitable access to immunotherapy and other treatment options will reduce cancer-related health disparities and improve survival of patients with HNSCC.

show abstract

Section: Clinical and Public Health Implicationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer

Ramkumar,

Bhardwaj,

Patel

et al. 2023

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

“…The new mAbs approved by the US Food and Drug Administration (FDA) for HNSCC patients are anti-PD-1 mAbs nivolumab and pembrolizumab [101], in addition to cetuximab, a mAb against epidermal growth factor receptor (EGFR) [102]. However, most do not benefit from anti-PD1 therapy.…”

Section: Immune-inflamed Cancer Phenotype and Benefit To Immunotherapymentioning

confidence: 99%

Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: A Focus on Tumor-Infiltrating Lymphocytes

Norouzian¹,

Balouchi-Anaraki

2019

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

For more progress in head and neck squamous cell carcinoma (HNSCC) immuno-oncology, further understanding of interactions between tumor and immune system as well as factors in the tumor microenvironment is required. HNSCC is seriously infiltrated by lymphocytes but is known to be highly immunosuppressive. The aim of this review is to highlight the complexity of tumor microenvironment and tumor- immune cells interaction in the HNSCC, in order to improve understanding of tumorigenesis and disease progression in HNSCC patient and to provide valuable information about prognostic markers. The main goal of this review is to discuss the role of the tumor infiltrating lymphocytes in tumor progression, their cross-talk with other components of the tumor microenvironment as well as their roles in carcinogenesis, metastasis process, treatment, and prognosis in head and neck squamous cell carcinomas.

show abstract

“…In recent years, several groups have leveraged this increased understanding of the immunobiology underlying tumor development and immunoediting to develop novel targeted immunotherapeutic strategies to reactivate the immune system [44][45][46]. The development of antagonist antibodies against immune checkpoint pathways have led to several successful drug approvals and effective implementation into clinical practice [47][48][49].…”

Section: Introductionmentioning

confidence: 99%

Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells

Clayton

Archard

Wagner

et al. 2020

Stem Cells and Development

View full text Add to dashboard Cite

Head and neck squamous cell carcinomas (HNSCCs) are malignancies that originate in the mucosal lining of the upper aerodigestive tract. Despite advances in therapeutic interventions, survival rates among HNSCC patients have remained static for years. Cancer stem cells (CSCs) are tumor-initiating cells that are highly resistant to treatment, and are hypothesized to contribute to a significant fraction of tumor recurrences. Consequently, further investigations of how CSCs mediate recurrence may provide insights into novel druggable targets. A key element of recurrence involves the tumor's ability to evade immunosurveillance. Recent published reports suggest that CSCs possess immunosuppressive properties, however, the underlying mechanism have yet to be fully elucidated. To date, most groups have focused on the role of CSC-derived secretory proteins, such as cytokines and growth factors. Here, we review the established immunoregulatory role of exosomes derived from mixed tumor cell populations, and propose further study of CSC-derived exosomes may be warranted. Such studies may yield novel insights into new druggable targets, or lay the foundation for future exosome-based diagnostics.

show abstract

Immune Checkpoint Inhibition in Cancers that Affect the Head and Neck

Cited by 4 publications

References 22 publications

Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer

Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer

Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: A Focus on Tumor-Infiltrating Lymphocytes

Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells

Contact Info

Product

Resources

About